A prospective study of Infliximab on Economic impacts, health outcomes and cost effectiveness in Chinese subjects with Rheumatoid Arthritis: A real world data.

Trial Profile

A prospective study of Infliximab on Economic impacts, health outcomes and cost effectiveness in Chinese subjects with Rheumatoid Arthritis: A real world data.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Infliximab (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2016 New trial record
    • 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top